{"organizations": [], "uuid": "b0f679ba769880b23dbd38281867f2893d2bec66", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2018/02/08/104997290-1920px-Kare_Schultz.1910x1000.jpg", "site_section": "", "section_title": "", "url": "https://www.cnbc.com/2018/02/08/teva-chief-reports-strong-progress-in-restructuring-plan.html", "country": "US", "domain_rank": 767, "title": "Teva chief reports 'strong progress' in restructuring plan", "performance_score": 0, "site": "cnbc.com", "participants_count": 0, "title_full": "", "spam_score": 0.04, "site_type": "news", "published": "2018-02-08T17:38:00.000+02:00", "replies_count": 0, "uuid": "b0f679ba769880b23dbd38281867f2893d2bec66"}, "author": "News Oresund", "url": "https://www.cnbc.com/2018/02/08/teva-chief-reports-strong-progress-in-restructuring-plan.html", "ord_in_thread": 0, "title": "Teva chief reports 'strong progress' in restructuring plan", "locations": [], "entities": {"persons": [{"name": "kare schultz", "sentiment": "negative"}, {"name": "schultz", "sentiment": "none"}, {"name": "kare shultz", "sentiment": "none"}], "locations": [], "organizations": [{"name": "teva", "sentiment": "negative"}, {"name": "pharmaceuticals teva", "sentiment": "negative"}, {"name": "teva pharmaceuticals", "sentiment": "none"}, {"name": "wikipedia", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "The chief executive of Teva Pharmaceuticals says he is making \"strong progress\" on the company's restructuring plan, but has acknowledged the generic drug giant faces a challenging 2018.\nKare Schultz, Teva's new CEO, provided the update as the company released its fourth-quarter earnings Thursday.\nTeva in December announced plans to cut 14,000 jobs, roughly one-quarter of its work force, in a broad restructuring as it confronts lower prices for generics, the expiration of patents on its core Copaxone drug and a more than $30 billion debt load.\nSpeaking to analysts, Schultz said roughly half the layoffs should be complete by July, with the remainder taking place by the end of 2019. \"Everything is on plan. Everything is on target,\" he said.\nTeva forecast lower revenue for 2018.", "external_links": [], "published": "2018-02-08T17:38:00.000+02:00", "crawled": "2018-02-08T17:38:37.041+02:00", "highlightTitle": ""}